Since then, it has been incorporated into the treatment of CD30+primary cutaneous anaplastic large cell lymphoma (pcALCL), peripheral T-cell lymphoma (PTCL), and mycosis fungoides (MF), etc., and has achieved significant efficacy (2–4). Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.